Company intelligence / Profile preview
HLB
Sejong Special Self-Governing City, South Koreahlbkorea.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Developing best-in-class targeted anticancer drug 'Rivoceranib' and next-generation immunotherapy vaccine platform 'UNITE'. Aiming to launch over 5 anticancer drugs by 2025.
- Therapeutic areas
- ImmunologyOncologyOphthalmologyNeurology
- Modalities
- Peptide drugstargeted anticancer drugsimmunotherapy vaccinesantibody-drug conjugatesCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on HLB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLB.